A randomised controlled psilocybin trial with 160 patients has been planned in Australia.
To conduct the study into treatment-resistant depression, @Swinburne signed a A$5m clinical trial research agreement with Woke Pharmaceuticals: https://swinburne.edu.au/news/2023/01/Australias-biggest-research-trial-using-psychedelics-to-treat-depression-to-commence-in-2023/
[email protected] CEO Jeff Stevens speaks about the company's legal #AmanitaMuscaria extract, and how there needs to be increased recognition of the #Wellness benefits of psychedelics as well as the medical.
🍄Psilocybin reduces binge eating episodes
🧠DMT-assisted therapy for major depressive disorder
🇦🇺Psilocybin trial planned with 160 patients in Australia
Read more in Issue 117 of The Psychedelics Newsletter: http://bit.ly/3XVTjAW
'One of the things that psilocybin can do is reset your whole outlook. Not to pretend that things haven’t happened, but to help you see what’s really important.'
Dr @anthony_back at @UW spoke with @qz on the potential of psychedelic healthcare:
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.